We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$440M
1-Year Est. Return
109.12%
This Fund
S&P 500
This Quarter
Est. Return
+11.1%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$440M
AUM Growth
+$9.07M
(+2.1%)
Cap. Flow
-$6.96M
Cap. Flow
% of AUM
-1.58%
Top 10 Holdings %
Top 10 Hldgs %
52.42%
Holding
87
New
10
Increased
20
Reduced
29
Closed
4
Top Buys
| 1 |
CMPS
Compass Pathways
CMPS
|
+$10.8M |
| 2 |
Nektar Therapeutics
NKTR
|
+$5.13M |
| 3 |
Larimar Therapeutics
LRMR
|
+$4.36M |
| 4 |
BCAX
Bicara Therapeutics
BCAX
|
+$2.76M |
| 5 |
Fulcrum Therapeutics
FULC
|
+$1.9M |
Top Sells
| 1 |
Cytokinetics
CYTK
|
+$9.76M |
| 2 |
Axogen
AXGN
|
+$7.38M |
| 3 |
ATXS
Astria Therapeutics
ATXS
|
+$3.99M |
| 4 |
Revolution Medicines
RVMD
|
+$2.41M |
| 5 |
State Street SPDR S&P Biotech ETF
XBI
|
+$2.25M |
Sector Composition
| 1 | Healthcare | 87.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Syndax Pharmaceuticals
SNDX
$2.12B
| $5.08M | 1.16% |
217,355
-60,500
| -22% | -$1.31M |
|
27
Alkermes
ALKS
$8.59B
| $4.93M | 1.12% |
139,482
+9,234
| +7% | +$286K |
|
28
Stoke Therapeutics
STOK
$1.84B
| $4.26M | 0.97% |
130,875
+22,000
| +20% | +$721K |
|
29
BioCryst Pharmaceuticals
BCRX
$2.39B
| $4.1M | 0.93% |
430,248
+11,993
| +3% | +$93.1K |
|
|
LKFT
30
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.93B
| $3.91M | 0.89% |
130,175
| – | – |
|
31
Immunovant
IMVT
$8.08B
| $3.74M | 0.85% |
150,524
| – | – |
|
32
Edgewise Therapeutics
EWTX
$4.33B
| $3.54M | 0.8% |
112,236
-47,500
| -30% | -$1.37M |
|
|
MPLT
33
MapLight Therapeutics
MPLT
$1.66B
| $3.48M | 0.79% |
171,006
+27,242
| +19% | +$487K |
|
34
Allogene Therapeutics
ALLO
$632M
| $3.34M | 0.76% |
1,370,118
-10,000
| -0.7% | -$20K |
|
35
Procept Biorobotics
PRCT
$1.08B
| $3M | 0.68% |
120,000
| – | – |
|
36
Align Technology
ALGN
$12.9B
| $2.57M | 0.59% |
15,000
-1,000
| -6% | -$175K |
|
37
ProQR Therapeutics
PRQR
$241M
| $2.54M | 0.58% |
1,567,561
| – | – |
|
|
HELP
38
Cybin Inc
HELP
$409M
| $2.39M | 0.54% |
498,361
+43,343
| +10% | +$280K |
|
|
RAPP
39
Rapport Therapeutics
RAPP
$1.93B
| $2.35M | 0.53% |
75,000
| – | – |
|
40
Insulet
PODD
$11.2B
| $2.28M | 0.52% |
10,870
+4,000
| +58% | +$1.01M |
|
41
Structure Therapeutics
GPCR
$3.43B
| $2.24M | 0.51% |
46,500
+9,500
| +26% | +$650K |
|
42
Immatics
IMTX
$1.29B
| $2.22M | 0.51% |
225,860
-35,278
| -14% | -$346K |
|
43
Celldex Therapeutics
CLDX
$3.01B
| $2.17M | 0.49% |
68,518
| – | – |
|
44
Lexeo Therapeutics
LXEO
$356M
| $2.16M | 0.49% |
377,059
+36,200
| +11% | +$257K |
|
45
Alector
ALEC
$164M
| $1.95M | 0.44% |
908,351
| – | – |
|
46
Viking Therapeutics
VKTX
$4.38B
| $1.94M | 0.44% |
59,516
| – | – |
|
47
Kura Oncology
KURA
$999M
| $1.92M | 0.44% |
235,868
| – | – |
|
|
PROF
48
Profound Medical
PROF
$257M
| $1.7M | 0.39% |
263,005
-22,705
| -8% | -$157K |
|
|
49
Fulcrum Therapeutics
FULC
$236M
| $1.57M | 0.36% |
+205,000
| New | +$1.9M |
|
50
Aquestive Therapeutics
AQST
$492M
| $1.53M | 0.35% |
368,415
-7,500
| -2% | -$30.4K |
|
Similar funds
FGWP
STCG
SCP
CAAM
AWM
HCM
CPW
DWML